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Abstract
Background: Abnormalities in the circadian clockwork often characterize patients with major depressive and bipolar
disorders. Circadian clock genes are targets of interest in these patients. CRY2 is a circadian gene that participates in
regulation of the evening oscillator. This is of interest in mood disorders where a lack of switch from evening to morning
oscillators has been postulated.
Principal Findings: We observed a marked diurnal variation in human CRY2 mRNA levels from peripheral blood
mononuclear cells and a significant up-regulation (P=0.020) following one-night total sleep deprivation, a known
antidepressant. In depressed bipolar patients, levels of CRY2 mRNA were decreased (P=0.029) and a complete lack of
increase was observed following sleep deprivation. To investigate a possible genetic contribution, we undertook SNP
genotyping of the CRY2 gene in two independent population-based samples from Sweden (118 cases and 1011 controls)
and Finland (86 cases and 1096 controls). The CRY2 gene was significantly associated with winter depression in both
samples (haplotype analysis in Swedish and Finnish samples: OR=1.8, P=0.0059 and OR=1.8, P=0.00044, respectively).
Conclusions: We propose that a CRY2 locus is associated with vulnerability for depression, and that mechanisms of action
involve dysregulation of CRY2 expression.
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Introduction
Rhythms that approximate the 24-hour day-night cycle or light-
dark transitions are called circadian. Abnormalities of the circadian
pacemaker system is often seen in mood disorders (i.e. major
depressive and bipolar disorders) as evidenced with sleep stage
abnormalities and the clinical efficacy of sleep deprivation [1] as
well as with the therapeutic mechanisms of lithium [2] that is
prescribed primarily for bipolar disorder. Approximately one tenth
of all mood disorders follow a seasonal pattern and area hence
categorized as seasonal affective disorder (SAD) [3]. Season-bound
mood episodes may occur in both depressive and bipolar disorders
and emerge in any season, but the most common type is winter
depression,aconditioninwhichmajordepressiveepisodesroutinely
occur in the wintertime and remit the following summer [4]. In one
study as much as 93% of the winter depressioncases had a diagnosis
of bipolar disorder [5] although other studies tend to show a greater
proportion of unipolar recurrent major depression among winter
depression cases [4]. Depressive episodes in winter depression are
highly recurrent and appear to be clearly endogenous as there is no
psychosocial factor that would account for their onset. For bipolar
type 1 disorder, the heritability estimate is very high [6]. Therefore,
winter depression, whether part of major depressive disorder or
bipolar disorder, as well as bipolar type 1 disorder, withor without a
seasonal pattern, provide excellent models for studying the
molecular mechanisms of mood disorder [7,8].
Advances and delays in phase (the location within a cycle at a
particular time) and reduced amplitudes (intensities of the
PLoS ONE | www.plosone.org 1 February 2010 | Volume 5 | Issue 2 | e9407oscillations) have been reported in adult patients [9–11], while
children with winter depression have circadian rhythms that are
accurate in phase but low in amplitude [12]. This agrees with the
hypothesis that not only phase shifts but also amplitude
attenuations [13] contribute to the pathogenesis, and suggests
that there are circadian clockwork abnormalities having relevance
to the daily reset and synchronization. This is further supported by
findings of the seasonal changes in sensitivity to light exposure in
winter depression, these patients having supersensitivity to light in
terms of melatonin suppression during winter [14], abnormal
melatonin levels in patients with seasonal or non-seasonal
depressive disorder [15], and abnormalities in circadian align-
ments in patients with bipolar disorder [16]. Therefore, the
internal misalignment (i.e. the sleep-wake cycle is no longer in
phase with the circadian rhythms) may account for the
pathogenesis of mood disorders in general. Light exposures and
sleep manipulations in patients with mood disorder are tools for
exploration and elucidation of the mechanisms driving the
circadian and seasonal clockworks.
CRY proteins [17] differ from many transcription factors that
take part in the circadian clockwork, since they have no PAS
domains. This suggests that they are unique in the core of the
circadian clockwork where they act [18]. Both CRY1 and CRY2
operate in the retina and non-visual light detection pathways in a
manner that is important for the internal alignment [19–24]. Of
these two, CRY2 is highly expressed in the brain in particular and
has a dose-dependent inhibitory effect on the activated ARNTL,
whereas both CRY2 and CRY1 repress all four combinations of
the ARNTL (ARNTL2) – CLOCK (NPAS2) protein heterodimers
that act as transcriptional activators in the core of the circadian
clockwork [25]. These basic findings give a rationale for the CRY2
gene as a target of high interest and relevance in our study.
Here, we assessed CRY2 gene expression in eight healthy
volunteers for 48 hours and in 13 patients with bipolar disorder
before and after a one-night sleep deprivation, and we report that
CRY2 mRNA levels are reduced and unresponsive to sleep
deprivation in depressed patients with bipolar disorder. To
determine whether CRY2 genetic variation is associated with
depression, we analyzed circadian clock gene variants in two
separate population-based samples, a Swedish sample and a
Finnish sample, and report that the CRY2 gene is associated with
winter depression.
Results
CRY2 Expression Analysis
CRY2 mRNA levels displayed marked diurnal variation in
healthy controls (n=8). In addition, total sleep deprivation
induced a 2.0-fold increase in CRY2 mRNA levels (P=0.020) in
the controls (Figure 1). The control gene GAPDH mRNA levels did
not show diurnal variation and were not changed by the effect of
sleep deprivation (P=0.66).
In samples from patients in a depressive state of bipolar disorder
(n=13), sleep deprivation did not induce any increase in CRY2
mRNA levels. CRY2 mRNA expression was significantly decreased
in the samples from patients as compared with the samples from
healthy controls during sleep deprivation (P=0.041 for the
diagnosis and sleep deprivation interaction using ANOVA;
P=0.029 for the difference between patients and controls during
sleep deprivation in post hoc test). GAPDH showed similar mRNA
Figure 1. CRY2 gene expression in healthy volunteers and bipolar disorder patients. CRY2 mRNA expression was not changed by sleep
deprivation in bipolar disorder patients (triangle) and was significantly decreased compared to healthy volunteers (square) during sleep deprivation.
Blood draw 1 (x-axis) was at 7 p.m., then there was a blood draw every 6 hours. Sleep deprivation was at time points #6, #7, #8 and #9. Bars
indicate mean and error bars indicate SEM.
doi:10.1371/journal.pone.0009407.g001
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samples (P=0.12).
Genetic Association Analysis
Analyses were performed on two samples of clinical cases with a
diagnosis of winter depression (DSM-IV) and healthy screened
controls (Swedish sample: 118 cases and 1011 controls, Finnish
sample: 86 cases and 1096 controls). CRY2 allele frequency was
significantly associated with winter depression in the Swedish
sample, as shown with three SNPs (rs10838524 risk allele A,
rs10838527 risk allele G, and rs3824872 risk allele A) having
OR=1.6, OR=2.1 and OR=1.8 (P=0.0017, P=0.00074 and
0.00070, respectively). The association to rs10838524 was
confirmed in the Finnish sample (OR=1.7, P=0.0020)
(Table 1) and indicated that homozygosity of the minor allele
(overall minor allele frequency of about 0.5) was increased in the
cases in both population samples (Table 2). The associated SNPs
(rs10838527 and rs3824872) were present in LD block 1
(rs7123390, rs10838527, rs3824872) in both samples (Figures 2A
and 2B).
Four haplotypes were identified and a significant difference in
distribution of haplotypes between the cases and controls was
found for the Swedish sample (x
2=8.7, P=0.034) and the Finnish
sample (x
2=14.6, P=0.0022; see Supplemental data Table S1). A
haplotype of the risk alleles GGA was more frequent in the
Swedish cases compared with controls (OR=1.7, P=0.012) and
even more so when adding the rs10838524 risk allele to the
haplotype to be AGGA (OR=1.8, P=0.0059; Table 3). The
block 1 (rs7123390, rs10838527, rs3824872) haplotype GAC
which in the Swedish sample has the protective alleles from
rs10838527 and rs3824872 was a risk haplotype in the Finnish
sample (OR=1.8, P=0.00010), and similarly so when adding the
rs10838524 allele G to the haplotype to be GGAC (OR=1.8,
P=0.00044; Table 3). The Finnish data suggest a vulnerability
locus increasing the risk for winter depression upstream
rs10838527. This was further supported by the fact that changing
only the rs7123390 allele in the Finnish risk haplotype (GAC)
turned it into a protective haplotype (AAC) in the Finnish sample
(OR=0.61, P=0.012), and the fact that the AGAC was non-
existent of in the samples. Considering only the Swedish data the
vulnerability locus could reside on either side of, but not exactly at
rs7123390. If assuming the same functional variation (although
probably opposite risk alleles in Swedes and Finns), the Swedish
and the Finnish samples together hence suggest the vulnerability
locus to reside in-between rs7123390 and rs10838527 or upstream
rs7123390 (Figure 2C).
Discussion
Our key findings herein are that CRY2 gene variation and
expression levels are associated with depression. CRY2 mRNA
levels are lowered in blood mononuclear cells from depressed
patients with bipolar disorder after total sleep deprivation in
comparison to healthy controls, and CRY2 gene variation was
associated with winter depression in both Swedish and Finnish
patients. Differences in CRY2 risk haplotypes were observed
between the Swedes and Finns. Overall there are genetic
differences between these populations [26]. The fact that Swedes
and Finns have different histories in terms of going through genetic
bottle-necks that could have affected selection in operation at the
CRY2 locus with regard to depression vulnerability, would possibly
explain the differences in CRY2 risk haplotypes seen between the
two samples, and explain a putative allelic heterogeneity (different
vulnerability alleles in Swedes and Finns) of the functional CRY2
polymorphism. Assuming the same functional variant in the
Swedish and the Finnish samples, the two samples would assist in
narrowing the interval of that functional variant (Fig. 2C). The risk
haplotypes spanned from CRY2 intron 1 to 39UTR, and pointed at
a location of a potential function variation somewhere upstream
exon 12 in 39UTR (rs10838527) from the Finnish data, with a
distance from the intron 1 marker rs10838524 to rs10838527
corresponding to ,33 kb (NCBI build 130). The vulnerability
locus from the Swedish data overlapped the Finnish locus, but for
at the intron 7 marker rs7123390, and extended downstream
rs10838527.
Human CRY2 mRNA levels have been demonstrated to
undergo circadian oscillation in fibroblasts [27] and in hemato-
Table 1. SNP allele frequency association analysis.
SNP Location Alleles MAF: A/U OR [95% CI]
a P value
a OR [95% CI]
b Empirical P
b,c
Swedish sample
rs10838524 Intron 1 A*/G 0.54/0.45 1.65 [1.21–2.25] 0.0017 1.41 [1.07–1.86] 0.013
rs7123390 Intron 7 (50 bp from
exon7)
A/G* 0.28/0.28 0.97 [0.69–1.37] 0.88 1.00 [0.73–1.40] 0.96
rs10838527 Exon 12 in 39 UTR G/A* 0.13/0.09 2.11 [1.37–3.26] 0.00074 1.73 [1.15–2.61] 0.010
rs3824872 Downstream 39 UTR A/C* 0.27/0.20 1.76 [1.27–2.43] 0.00070 1.49 [1.09–2.04] 0.014
Finnish sample
rs10838524 Intron 1 G/A* 0.60/0.47 1.69 [1.21–2.36] 0.0020 1.72 [1.24–2.39] 0.0021
rs7123390 Intron 7 (50 bp from
exon7)
A/G* 0.19/0.29 0.60 [0.40–0.91] 0.015 0.59 [0.40–0.87] 0.016
rs10838527 Exon 12 in 39 UTR G/A* 0.089/0.13 0.68 [0.39–1.19] 0.18 0.68 [0.39–1.19] 0.18
rs3824872 Downstream 39 UTR A/C* 0.20/0.26 0.70 [0.47–1.05] 0.089 0.70 [0.47–1.05] 0.089
Alleles, minor allele first.
OR, proportion of minor versus major allele among affected (A)/proportion of minor versus major allele among non-affected (U).
aLogistic regression with gender as covariate. P,0.05 are shown.
bNo covariate.
cPoint-wise P-value from 10,000 permutations with no covariate (EMP1).
*Ancestral allele in CEU population data (CEPH (Utah residents with ancestry from northern and western Europe)) from www.hapmap.org.
doi:10.1371/journal.pone.0009407.t001
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and demonstrate the effect of sleep deprivation on the circadian
oscillations of CRY2 mRNA in human peripheral blood mononu-
clear cells. Our data indicate that depression in bipolar disorder is
related to lowered levels of CRY2 mRNA. Sleep deprivation led to
CRY2 mRNA increase in controls whereas depressed bipolar
individuals were non-responsive.
CRY2 has been purified from human cells and its properties
have been described [29], but the understanding of CRY2
regulation and CRY2 functions still need elucidation. Earlier
studies have demonstrated that CRY2 t r a n s c r i p t i o ni sd r i v e nb y
the canonical circadian circuit but through a unique mechanism
of action not yet characterized [30–32]. CRY2 is unique among
the canonical genes of the circadian clock, since experimental
findings of its effects on the circadian clockwork violate the
predictions from a theory on the roles of PER1, PER2, CRY1
and CRY2 [33–36]. Deletion of Cry2 gene lengthened the
circadian period by approximately 48 min (from 23.7 to
24.5 hours) [37] and in fact strengthened circadian amplitudes
and restored the lost rhythms in Per2 mutant mice [38,39]. These
findings fit in the view that activation of Per1 and Per2 genes
occurs in the morning, whereas activation of Cry1 and Cry2 genes
occurs in the evening [40]. Abnormalities in CRY2 regulation
would therefore leave the morning oscillator intact, which agrees
Figure 2. The suggested vulnerability locus in CRY2. LD structure of the SNPs analyzed in A) the Swedish sample, and B) the Finnish sample. C)
Scheme of the suggested location of the functional variant in the Finnish sample, in the Swedish sample, and the common locus relevant under the
assumption of the same functional variant in the two samples. An open end of locus box (seen for the Swedish sample) indicates that this is not the
locus border. The numbers in the squares of A and B) represent the pair-wise D’ value, empty squares stand for D’=1. Pink-red color indicates a pair-
wise LOD $2 with redness proportional to D’. Haplotype blocks are formed if 95% of comparisons are ‘‘strong LD’’, i.e. the 95% CI of D’ is within [0.7–
0.98].
doi:10.1371/journal.pone.0009407.g002
Table 2. Genotype association analysis of the SNPs with suggestive allele frequency association.
SNP
Cases aa/
ab/bb (%)
Cases
n
Controls aa/
ab/bb (%)
Controls
n
Cochran-Armitage
trend P value
Minor allele
dominant P
Minor allele
recessive P
Swedish sample
rs10838524 30/48/22 113 20/51/29 906 0.014 0.14 0.011
rs10838527 3.5/20/76 113 0.52/16/84 951 0.0085 0.048 0.010
rs3824872 13/28/58 113 4.2/32/64 927 0.014 0.27 0.000041
Finnish sample
rs10838524 38/43/18 76 22/49/29 1 039 0.0015 0.047 0.0014
rs7123390 3.8/32/64 78 7.9/42/52 1 066 0.014 0.019 0.27
Allele ‘a’ is the minor allele.
Note that the identity of the rs10838524 minor allele differs between the Swedish and Finnish samples.
doi:10.1371/journal.pone.0009407.t002
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with bipolar disorder [42]. However, disruption of CRY2
regulation may compromise the evening oscillator and the
subsequent proper oscillator reactions to light-dark transitions
[43]. Cry2 null mutants are less decelerated, or are more
accelerated, by light exposure than Cry1 null mutants [36]. The
former phenotype does match with that seen in winter
depression [44] and, to some extent, in bipolar type 1 disorder
[45].
The action of melatonin on Cry1/Cry2 expression is hypothe-
sized to form the basis of refractory reactions to stimulation with
light [40], and the subsequent subsensitive or supersensitive
responses to light exposure. Phase control through the melatonin-
guided interval of Per1/Per2 to Cry1/Cry2 expression peaks may
have relevance to mood disorders, as the internal alignment and
the melatonin signal (amplitude and phase) are abnormal in
patients with bipolar disorder and those with winter depression in
particular [15,16,46]. Our findings now suggest that a dawn
component [47,48] and a dusk component (herein), i.e. PER2 and
CRY2 variants respectively, are affected in winter depression. Such
influence may well contribute to phase angle differences [49] and
entrainment errors [11] that have been found in patients with
winter depression.
To sum up, the phenotype of the Cry2 knockout mice together
with mechanistic data are in line with the finding in this report
suggesting that CRY2 has a role in winter depression.
Our current findings add to earlier gene expression studies in
blood that have reported a number of potential peripheral
biomarkers for bipolar disorder [50,51], and earlier gene
expression findings in brain indicating that clock genes are
implicated in a model of bipolar disorder, the first report being
[52], followed by [53] for CRY2. Circadian genes with a
polymorphism previously reported to be associated to human
bipolar disorder include CLOCK [54], and NR1D1, ARNTL and
PER3 [55–57]. Moreover, ARNTL, RORA, RORB and RXRG were
associated with bipolar disorder in a meta-analysis integrating data
from genome-wide association studies and human and animal
model expression studies [51]. PER2, NPAS2 and ARNTL genetic
variation have been found associated with winter depression
[47,48,58], and recent experimental data demonstrated these
three proteins to regulate transcription of MAOA and to have
subsequent influence on depressive behavior [59].
Other circadian genes were tested for association to winter
depression in parallel with CRY2. The CRY2 finding reached
significance even after correction for multiple testing considering
other circadian gene SNPs tested for association to winter
depression in parallel with CRY2. The corrected threshold for
significance corresponded to a nominal P-value of 0.001 and was
calculated applying a Bonferroni correction considering the partial
LD between markers [60,61]. As a novel finding we report here
that CRY2 expression is reduced and non-responsive to sleep
deprivation in depressed patients with bipolar disorder, suggesting
that CRY2 plays a role in bipolar disorder.
There are some limitations in our work. A limitation in the
CRY2 expression analysis was the few time points for the cases,
since they do not allow analysis of the CRY2 rhythm and possible
phase shift among the cases. However, irrespectively of whether
there was a phase shift or not among the cases, CRY2 mRNA
levels were significantly lower in cases compared to controls after
sleep deprivation, which suggests that CRY2 levels is a trait
marker that is non-responsive to the antidepressant sleep
deprivation. Though, we cannot exclude that the CRY2 mRNA
levels in the patients were influenced by medication. All the
patients were on an SSRI together with a mood stabilizer.
Lithium is known to affect the circadian clock through inhibition
of GSK3 [2], and there are reports of SSRI influencing the
circadian rhythms [62]. Since all controls and 10 of the patients
were studied during the summer, the season of the examinations
does not likely explain the CRY2 mRNA level difference between
patients and controls. A limitation in the genetic analysis was the
number of patients. However, the cases and the controls in both
the Swedish and the Finnish materials represented ethnically
homogeneous populations, and the controls were extensively
scored to exclude any mental illness, reducing bias due to the
ethnic variation and dilution of genetic effects due to disorder
heterogeneity among the controls.
In conclusion, we show data suggesting that variation in CRY2
links to depression. CRY2 mRNA expression levels were lowered in
PBMCs from depressed patients with bipolar disorder. In two
ethnically homogeneous population-based samples, CRY2 SNPs
Table 3. Haplotype association analysis.
SNPs Haplotype Frequency cases Frequency controls OR [95% CI] P value
Swedish sample
rs7123390-rs10838527-rs3824872 GGA 0.14 0.090 1.68 [1.13–2.53] 0.012
rs7123390-rs10838527-rs3824872 GAC 0.44 0.52 0.74 [0.56–0.97] 0.032
rs10838524-rs7123390-rs10838527-
rs3824872
AGGA 0.14 0.082 1.82 [1.17–2.63] 0.0059
rs10838524-rs7123390-rs10838527-
rs3824872
GGAC 0.44 0.51 0.75 [0.57–0.98] 0.048
Finnish sample
rs7123390-rs10838527-rs3824872 AAC 0.21 0.29 0.61 [0.42–0.90] 0.012
rs7123390-rs10838527-rs3824872 GAC 0.59 0.45 1.84 [1.35–2.55] 0.00010
rs10838524-rs7123390-rs10838527-
rs3824872
AAAC 0.20 0.27 0.67 [0.45–0.98] 0.046
rs10838524-rs7123390-rs10838527-
rs3824872
GGAC 0.59 0.45 1.76 [1.31–2.47] 0.00044
Odds ratio (OR): the ratio specific haplotype versus all other haplotypes among the cases, relative to the ratio specific haplotype versus all other haplotypes among the
controls.
doi:10.1371/journal.pone.0009407.t003
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contains a replication of the genetic findings, it remains limited
due to the lack of replication of the expression findings, thus
warranting further studies.
Methods
CRY2 Expression Study
Informed consent was obtained from each participant using an
approved University of California Institutional Review Board
(IRB) protocol.
Thirteen patients (10 men, 3 women, out of which 11 with
European, one with Asian and one with African decent) with
bipolar type 1 disorder according to DSM-IV criteria, aged 40.2
years on average (SD=13.4, range=18–57), were enrolled in a
sleep deprivation study at University of California Irvine (UCI)
and San Diego (UCSD). During the study, all the patients were
depressed, with the score on the 21-item Hamilton Depression
Rating Scale [63] being 17.3 (SD=6.4) on average. Eight healthy
volunteers (4 women, 4 men, all with European decent), aged 23.6
years on average (SD=5.9, range=19–34 years), served as
controls. Both the patients and the controls were hospitalized at
the sleep research center at University of California at Irvine
Medical Center (UCIMC) for 48 hours and deprived of sleep for
21 hours after an overnight stay (Figure 2). The season for the
study of the patients was summer (n=10) and winter (n=3), and
all controls were studied in the summer. All the patients were on
an SSRI and either lithium (n=8), valproate (n=1) or lamotrigine
(n=4). None of the controls was on medication.
For the controls, venous blood samples were drawn at 9
different times, beginning at 7 p.m. and every 6 hours
thereafter. For the patients, the blood was drawn at 1 p.m. on
the days before and after sleep deprivation, corresponding to
t h et i m ep o i n t s#4a n d#8 for the control samples. The patient
blood was drawn in standard Vacutainer tubes without additive
(10 ml, Becton Dickinson, Franklin Lakes, NJ, USA). From
each control the blood was collected into both a standard acid
citrate dextrose (ACD) tube (Becton Dickinson, Franklin Lakes,
NJ, USA) as well as a Tempus Blood RNA Tube (Applied
Biosystems, Foster City, CA, USA) in the same blood draw,
yielding the total of 25–35 ml of whole blood. To check for
potential difference in RNA degradation between control and
bipolar disorder samples, the level of the house-keeping
transcript GAPDH (glyceraldehyde-3-phosphate dehydroge-
nase) was analyzed with qPCR (data in the results section). To
further rule out possible bias in comparison between the
patients and controls due to type of collection tube, we
compared CRY2 and GAPDH mRNA levels using qPCR
between the Tempus tube and the ACD tube from the controls
collected at the same blood draw. The CRY2 and GAPDH
mRNA levels were not different between tube types (data not
shown).
Peripheral Blood Mononuclear Cells (PBMC) Isolation and
RNA Extraction
All samples from both the patients and the controls were
prepared similarly. Within a few minutes in room temperature
after blood draw, the whole blood samples were layered onto Ficoll
(Amersham Biosciences, Piscataway, NJ, USA), and PBMC were
separated by density gradient centrifugation at 2500 rpm at room
temperature for 20 min. The resulting ‘buffy’ coat at the interface
was added to 5 ml phosphate buffered saline (PBS) at pH of 7.4
(Invitrogen, Carlsbad, CA, USA) and cell counts were taken. Cells
were centrifuged at 1000 rpm for 10 min at room temperature.
The resulting pellets were resuspended in 1 ml Trizol and stored
at minus 80uC. Total RNA was extracted using the standard
Trizol isolation protocol (Invitrogen, Carlsbad, CA, USA). The
RNA was resuspended in 50 mL DEPC water, cleaned by passing
over silica-based mini-spin columns (Qiagen RNeasy PlusMini
Kit, Valencia, CA, USA) and analyzed for quality and quantity on
a 2100 Bioanalyzer (Agilent, Palo Alto, CA, USA) and
concentration was adjusted to 1 mg/ml.
Real Time Quantitative PCR (qPCR)
The total RNA (1 mg RNA) from both the patients and the
controls were identically synthesized into complementary DNA
(cDNA) using Oligo d(T)16 primer and TaqMan Reverse
Transcription Reagents and (Applied Biosystems, Foster City,
CA, USA) at 25uC for 10 min, 48uC for 30 min and 95uCf o r
5 min. The quantitative PCR (qPCR) was performed on an ABI
7900HT Sequence Detection System (Applied Biosystems, Foster
City, CA, USA) with triplicates for each cDNA, using Robot
Biomek3000 (Beckman Coulter, Fullerton, CA, USA), with all
samples run in the same plates with same normalization
procedures. The reaction was performed in 12.5 ml consisting of
6.25 ml 2xSYBR Green Master Mix (Applied Biosystems, Foster
City, CA, USA); 2.5 pmol of each primer; 2 ml 1:10 dilution of
cDNA template (corresponding approximately to 4 ng RNA).
The thermal cycling profiles were 50uC for 2 min (incubation),
95uC for 10 min (activation), 45 cycles at 95uC for 15 sec
(denaturation) and 60uC for 1 min (annealing/extension), then by
dissociation step as 95uC for 15 sec, 60uC for 15 sec, and 95uCf o r
15 sec. The CRY2 primer sequences spanned exon 6–7 junction
within target sequence (Affymetrix probeset 3329058, transcript
ID 3329029) and were: forward 59-CCTACCTGCGCTTT-
GGTTGT-39, reverse 59-TGCTGTTCCGCTTCACCTTT-39.
The primers were pre-tested using brain cDNA, genomic DNA,
notemple control(NTC)and RT minusonthe ABI7900HT.The
results ensured good amplification of cDNA, and that neither
residual genomic DNA nor primer-dimer contributed to
measurements.
Genetic Association Study
The local ethic committees (National Public Health Institute,
Karolinska Institutet, and University of Umea ˚) approved the study
protocol, and all the participants signed an informed consent after
the protocol had been fully explained.
Patients were recruited from outpatient services at which senior
specialists in psychiatry, familiar with our research program, were
working. All patients met the DSM-IV diagnostic criteria for
major depressive disorder with the seasonal (winter) pattern [64].
The consensus diagnosis of two independent psychiatrists was
required for inclusion for each patient. Patients were from Sweden
(118 patients: 13.6% men, 86.4% women) and Finland (86
patients: 29.1% men, 70.9% women), both being of local origin.
Controls matched for ethnicity and nationality (1011 Swedes:
39.2% men, 60.8% women; and 1096 Finns: 29.0% men, 71.0%
women) had no current or past psychotic or mood disorder as
assessed with interviews or self-rated questionnaires and were
representative of the Swedish and Finnish adult populations.
These population-based studies have been described more in detail
earlier [65–67]. The Swedish cases and controls lived in Va ¨ster-
botten and Stockholm areas. The Swedish population has no
strong internal genetic borders [24]. The Finnish cases lived in the
capital area (Helsinki and its surroundings), with inhabitants from
all the regions in Finland, and the controls were collected from the
nation-wide health examination study.
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Haplotype-tagging SNPs covering the variation in CRY2 were
selected using the HapMap database [68], applying the cut-off
values of 0.8 for r
2 and of 0.1 for the minor allele frequency
(MAF). The genotyping was performed using the SEQUENOM
iPLEX Application with the MassARRAY System (Sequenom,
Inc., San Diego, CA, USA). To control for quality, 2.5% of the
samples were genotyped in duplicates. The genotypes of these
replicas were all in agreement.
The four CRY2 SNPs genotyped fulfilled the criteria for SNP
association test including a success rate of at least 90% of the
reactions, and the Hardy-Weinberg equilibrium (HWE) with
P.0.05 among the controls. The DNA samples from 10 Swedish
cases and 53 controls, and 5 Finnish cases and 24 controls were
excluded from analysis, since genotyping of them failed in more
than 20% of a separate set of 111 SNP assays.
Statistical Analyses
For the RNA analysis, the cycle threshold (Ct) was determined
approximately in the middle of exponential phase of the
amplification, and generally default condition on the software
SDS 2.3 was used. The average Ct value was accepted if the CV
was lower than 2% and SD was lower than 0.39. The Ct values for
CRY2 and the house-keeping gene GAPDH were normalized using
the housekeeping genes C1ORF82 and TFG. The selection of
C1ORF82 and TFG and the normalization method was based on
the GENORM [69]. Within each of the case and the control
groups, correlation for CRY2 and GAPDH expression levels to age
was tested and showed no significant correlation. Among controls,
the CRY2 and GAPDH expression levels were compared between
pre-sleep deprivation time points (pooled time points from #1t o
#4) and sleep deprived time points (pooled time points from #6t o
#9), where the individual was used as a factor in a mixed model
ANOVA.
CRY2 and GAPDH expression levels comparison between
bipolar patients (time point 1 p.m.) and controls (pooled time
points from #1t o#4, and from #6t o#9) was done using
ANOVA with the covariates gender, age and sleep deprivation
(yes/no). Significant effect in ANOVA (p,0.05) was followed-up
with post hoc test.
The SNPs were analyzed for allele frequency differences
between the cases and controls in each population sample using
logistic regression. Gender was used as a covariate, since women
were overrepresented among Swedish cases compared with
controls. To obtain empirical significance values, permutation
tests with up to 10,000 permutations were performed. There was a
similarity between the gender corrected effect size and the effect
size when no gender was corrected for, especially in the Finnish
sample (Table 1). Hence, the gender was not generally controlled
for in the subsequent analyses. However, suggestive genotypic
association findings in the Swedish sample were verified using
logistic regression with the gender as a covariate, and displayed a
very minor gender effect. The power was $0.8 to detect allele
frequency differences at odds ratio (OR) of $1.8 in the Swedish
sample and at OR of $2.0 in the Finnish sample when the MAF
was of 0.1 to 0.3 and the non-corrected P was of ,0.05 (http://
pngu.mgh.harvard.edu/,purcell/gpc/cc2.html). Those SNPs
whose allele frequency difference was indicative (P,0.05) were
analyzed for genotype association. Calculations were performed
using the PLINK program, version 1.04 [70].
The linkage disequilibrium (LD) measure D’ was calculated
between the SNPs using the Haploview program, version 3.2 [71],
which applies an approach similar to the partition-ligation-
expectation-maximization algorithm [72]. Haplotype blocks were
constructed using the LD block parameters [73], and the D’
confidence interval algorithm in the Haploview program. Tests for
haplotype frequency difference between the cases and controls
were calculated for the haplotype blocks harboring the SNPs
having P of ,0.05 for allele association using the Haploview
program. The SNP rs10838524 in CRY2 was included in
haplotype analysis even though it was not included in any block
but was nearby and associated as a single SNP with winter
depression.
Supporting Information
Table S1 All the detected haplotypes of the CRY2 block.
Found at: doi:10.1371/journal.pone.0009407.s001 (0.04 MB
DOC)
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